Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/2020

Open Access 01-01-2020 | Correction

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy

Authors: Nadia Mensali, Marit Renée Myhre, Pierre Dillard, Sylvie Pollmann, Gustav Gaudernack, Gunnar Kvalheim, Sébastien Wälchli, Else Marit Inderberg

Published in: Cancer Immunology, Immunotherapy | Issue 1/2020

Login to get access

Excerpt

The original version of this article unfortunately included a mistake in Fig. 2b where the images of mice in the tumour control group (right), day 30 (bottom) should be removed as the wrong images (duplicate of day 17) were inserted by mistake. At this time point the tumour control mice were no longer alive and the images were replaced by black areas. …
Metadata
Title
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Authors
Nadia Mensali
Marit Renée Myhre
Pierre Dillard
Sylvie Pollmann
Gustav Gaudernack
Gunnar Kvalheim
Sébastien Wälchli
Else Marit Inderberg
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 1/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02409-6

Other articles of this Issue 1/2020

Cancer Immunology, Immunotherapy 1/2020 Go to the issue

Editorial

Solid pavestones are needed to pave a solid way to success

Original Article

VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer

Original Article

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Original Article

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer

Original Article

Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells

Original Article

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits